Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Codeine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 11/20 | 0.91 |
| ▸ | OPRK1 known ✓ | P41145 | 9/20 | 0.91 |
| ▸ | OPRD1 known ✓ | P41143 | 8/20 | 0.91 |
| ▸ | MRGPRX2 | Q96LB1 | 4/20 | 0.91 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.91 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.91 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.91 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.85 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.85 |
| ▸ | ARRB1 | P49407 | 1/20 | 0.85 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Codeine SCHEMBL156020 | 0.96 | OPRM1 (0.86) | OPRM1OPRK1OPRD1MRGPRX2ADRB1 | |
| Codeine SCHEMBL28426831 | 0.96 | OPRM1 (0.86) | OPRM1OPRK1OPRD1MRGPRX2ADRB1 | |
| Codeine SCHEMBL8218174 | 0.95 | OPRD1 (1.00) | OPRM1OPRK1OPRD1MRGPRX2ADRB1 | |
| Codeine SCHEMBL10329428 | 0.95 | OPRD1 (1.00) | OPRM1OPRK1OPRD1MRGPRX2ADRB1 | |
| Codeine SCHEMBL1276342 | 0.95 | OPRD1 (1.00) | OPRM1OPRK1OPRD1MRGPRX2ADRB1 | |
| Codeine SCHEMBL14371354 | 0.95 | OPRD1 (1.00) | OPRM1OPRK1OPRD1MRGPRX2ADRB1 | |
| Codeine SCHEMBL1560699 | 0.95 | OPRD1 (1.00) | OPRM1OPRK1OPRD1MRGPRX2ADRB1 | |
| Codeine SCHEMBL13696342 | 0.95 | OPRD1 (1.00) | OPRM1OPRK1OPRD1MRGPRX2ADRB1 | |
| Codeine SCHEMBL21077535 | 0.95 | OPRD1 (1.00) | OPRM1OPRK1OPRD1MRGPRX2ADRB1 | |
| Codeine SCHEMBL3257 | 0.95 | OPRD1 (1.00) | OPRM1OPRK1OPRD1MRGPRX2ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-210243621-U | Food morphine rapid detection kit | ZHEJIANG HUACAI DETECTION TECHNOLOGY CO., LTD. | 2020-04-03 | — | — | CN | claimed |
| CN-109932493-A | A kind of food morphine quick detection kit | 浙江华才检测技术有限公司 | 2019-06-25 | — | — | CN | claimed |
| US-20240218408-A1 | Methods of Producing Epimerases and Benzylisoquinoline Alkaloids | HERCULES CAPITAL, INC., AS AGENT | 2024-07-04 | — | — | US | disclosed |
| US-20240102061-A1 | METHODS OF IMPROVING PRODUCTION OF MORPHINAN ALKALOIDS AND DERIVATIVES | HERCULES CAPITAL, INC., AS AGENT | 2024-03-28 | — | — | US | disclosed |
| US-20240002403-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 4-((6bR,10aS)-3-METHYL2,3,6b,9,10,10a-HEXAHYDRO-1H-PYRIDO[3',4':4,5]PYRROLO[1,2,3-de]QUINOXALIN8(7H)-YL)-1-(4-((6bR,10aS)-3-METHYL-2,3,6b,9,10,10a-HEXAHYDRO-1HPYRIDO[3',4':4,5]PYRROLO[1,2,3-de]QUINOXALIN-8(7H)-YL)PHENYL)BUTAN-1-ONE FOR TREATING CONDITIONS OF THE CENTRAL NERVOUS SYSTEM AND CARDIAC DISORDERS | INTRA-CELLULAR THERAPIES, INC. | 2024-01-04 | — | — | US | disclosed |
| US-11859225-B2 | Methods of producing epimerases and benzylisoquinoline alkaloids | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2024-01-02 | — | — | US | disclosed |
| EP-4253525-A2 | METHODS OF PRODUCING EPIMERASES AND BENZYLISOQUINOLINE ALKALOIDS | The Board of Trustees of the Leland Stanford Junior University (US) | 2023-10-04 | — | — | EP | disclosed |
| US-11753419-B2 | 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)phenyl)butan-1-one for treating conditions of the central nervous system and cardiac disorders | INTRA-CELLULAR THERAPIES, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-20230104286-A1 | METHODS OF PRODUCING NOR-OPIOID AND NAL-OPIOID BENZYLISOQUINOLINE ALKALOIDS | HERCULES CAPITAL, INC., AS AGENT | 2023-04-06 | — | — | US | disclosed |
| US-20230021717-A1 | ORGANIC COMPOUND | INTRA-CELLULAR THERAPIES, INC. | 2023-01-26 | — | — | US | disclosed |
| US-11427827-B2 | Engineered benzylisoquinoline alkaloid epimerases and methods of producing benzylisoquinoline alkaloids | ANTHEIA, INC. (US) | 2022-08-30 | — | — | US | disclosed |
| EP-1053303-A1 | CYTOCHROME P450 REDUCTASES FROM POPPY PLANTS | JOHNSON & JOHNSON RESEARCH PTY LIMITED (AU) | 2000-11-22 | — | — | EP | disclosed |
| US-6080740-A | Spiro-ketal derivatives and their use as therapeutic agents | MERCK SHARP & DOHME LTD. (GB) | 2000-06-27 | — | — | US | disclosed |
| EP-0912577-A2 | NOVEL METHODS OF O-DEMETHYLATION AND N-DEPROTECTION | THE UNITED STATES OF AMERICA, as represented by the Secretary of the Department of Health and Human Services (US) | 1999-05-06 | — | — | EP | disclosed |
| WO-1999011765-A1 | CYTOCHROME P450 REDUCTASES FROM POPPY PLANTS | JOHNSON & JOHNSON RESEARCH PTY. LIMITED (AU) | 1999-03-11 | — | — | WO | disclosed |
| EP-0858329-A1 | NOVEL STABLE LIQUID PARACETAMOL COMPOSITIONS, AND METHOD FOR PREPARING SAME | SCR Pharmatop (FR) | 1998-08-19 | — | — | EP | disclosed |
| WO-1997044317-A9 | NOVEL METHODS OF O-DEMETHYLATION AND N-DEPROTECTION | — | 1998-06-25 | — | — | WO | disclosed |
| WO-1998005314-A1 | NOVEL STABLE LIQUID PARACETAMOL COMPOSITIONS, AND METHOD FOR PREPARING SAME | SCR PHARMATOP (FR) | 1998-02-12 | — | — | WO | disclosed |
| WO-1997044317-A2 | NOVEL METHODS OF O-DEMETHYLATION AND N-DEPROTECTION | THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1997-11-27 | — | — | WO | disclosed |
| US-4160016-A | Receptor fluorescent immunoassay | SYVA COMPANY (US) | 1979-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240002403-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 4-((6bR,10aS)-3-METHYL2,3,6b,9,10,10a-HEXAHYDRO-1H-PYRIDO[3',4':4,5]PYRROLO[1,2,3-de]QUINOXALIN8(7H)-YL)-1-(4-((6bR,10aS)-3-METHYL-2,3,6b,9,10,10a-HEXAHYDRO-1HPYRIDO[3',4':4,5]PYRROLO[1,2,3-de]QUINOXALIN-8(7H)-YL)PHENYL)BUTAN-1-ONE FOR TREATING CONDITIONS OF THE CENTRAL NERVOUS SYSTEM AND CARDIAC DISORDERS | HTR1A, HTR2C, HTR1B | OPRM1 90/4885OPRK1 44/4885OPRD1 60/4885 |
| US-20230021717-A1 | ORGANIC COMPOUND | SLC6A2, SLC6A4, SLC6A3 | OPRM1 39/4885OPRK1 31/4885OPRD1 25/4885 |
| US-11753419-B2 | 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)phenyl)butan-1-one for treating conditions of the central nervous system and cardiac disorders | HTR1A, TPH1, HTR2C | OPRM1 95/4885OPRK1 54/4885OPRD1 58/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.